Home › Funds › DSM CAPITAL PARTNERS LLC › BSX

DSM CAPITAL PARTNERS LLC position in BSX

BOSTON SCIENTIFIC CORP · Health Care

DSM CAPITAL PARTNERS LLC reported holding 511,968 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$21.9M, representing 0.37% of its reported portfolio and ranking #31 among its reported holdings. DSM CAPITAL PARTNERS LLC has disclosed BSX holdings in 10 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)511.97K sh
Reported value held$21.85M
Portfolio Weight0.37%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DSM CAPITAL PARTNERS LLC's BSX position evolved

DSM CAPITAL PARTNERS LLC first disclosed a stake in BSX in Q3 2023 at 2,393,829 shares (US$126.4M). The position peaked in Q4 2023 at 2,838,623 shares, worth US$164.1M. Across 10 filings, DSM CAPITAL PARTNERS LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 511,968 shares valued at US$21.9M — a reduction of -52,381 shares quarter over quarter.. Notable position changes include a 100% trim in Q2 2024 (shares rose 9% over the following quarter), a 39% increase in Q3 2025 (shares fell 2% over the following quarter), a 11846% increase in Q1 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.39M $126.39M New
Q4 2023 2.84M $164.10M Add
Q1 2024 2.17M $148.56M Reduce
Q2 2024 1.32K $101.96K Reduce
Q3 2024 1.32K $110.95K Hold
Q2 2025 2.86K $306.98K New
Q3 2025 3.98K $388.27K Add
Q4 2025 4.72K $450.43K Add
Q1 2026 564.35K $35.41M Add
Q2 2026 511.97K $21.85M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has DSM CAPITAL PARTNERS LLC held BSX?

DSM CAPITAL PARTNERS LLC has disclosed BSX holdings in 10 of the last 12 reported quarters, going back to Q3 2023.

What is DSM CAPITAL PARTNERS LLC's current position in BSX?

As of Q2 2026, DSM CAPITAL PARTNERS LLC holds 511.97K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $21.85M, representing 0.37% of its reported portfolio and ranking #31.

Has DSM CAPITAL PARTNERS LLC been buying or selling BSX?

In the latest 13F filing (Q2 2026), DSM CAPITAL PARTNERS LLC reduced its position in BSX. The position peaked in Q4 2023 at 2.84M shares.

Which other funds hold BSX?

Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.